The ADAM9 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte line. Through targeted disruption of the ADAM9 gene, these cells serve as a versatile loss-of-function model for dissecting the roles of the ADAM9 metalloprotease in immune cell biology. As a polyclonal pool, the product avoids biases introduced by single-cell cloning and reflects the heterogeneous editing outcomes typical of bulk CRISPR approaches, making it well-suited for population-level functional assays.
The parental Jurkat cell line is an immortalized T lymphocyte model established from the peripheral blood of a patient with acute T cell leukemia. Jurkat cells are extensively used to study T cell receptor signaling, cytokine production, and leukemogenesis, offering a tractable system for genetic manipulation and downstream molecular characterization. Their derivation from a malignant T-cell context renders them particularly relevant for examining oncogenic signaling networks and metastatic mechanisms.
ADAM9 encodes a transmembrane metalloprotease that sheds ectodomains of membrane-anchored proteins, including EGFR ligands HB-EGF and amphiregulin, and Notch ligand Delta-like 1. Regulated by EGF, TGF-alpha, TNF-alpha, AP-1, and Src kinases, ADAM9 transactivates EGFR and Notch receptors, engaging GRB2?CRAS?CRAF?CMEK?CERK and PI3K?CAKT cascades. ADAM9 interacts with integrins alphaV/beta3 and alpha6/beta1, tetraspanins CD9 and CD81, and ADAM10/ADAM17, coordinating focal adhesion dynamics and matrix organization. Through these interactions, ADAM9 modulates cell adhesion, migration, and proliferation.
In Jurkat cells, ADAM9 knockout impairs shedding of HB-EGF and Delta-like 1, attenuating autocrine/paracrine activation of EGFR and Notch pathways. This dampens integrin signaling and focal adhesion turnover, critical for T cell adhesion and migration. Thus, the model reveals how ADAM9-dependent shedding governs T cell motility, invasion, and survival in leukemia, and facilitates study of crosstalk with ADAM10 and ADAM17 in immune signaling.
Researchers can employ these polyclonal knockout cells in a range of functional assays, including transwell migration and cell adhesion assays to assess motility, shedding assays to quantify HB-EGF release, and phospho-EGFR western blotting to monitor receptor transactivation. Additionally, flow cytometry and RT-qPCR enable confirmation of ADAM9 loss and transcriptomic profiling via RNA-seq, while proliferation assays gauge growth changes. The model is ideal for screening ADAM9 inhibitors, studying T cell adhesion and migration in leukemia, exploring EGFR transactivation in cancer, and advancing cancer metastasis research. For additional information, please contact Ascent Research.
